Rep. Jared Moskowitz Sells Off Shares of Elevance Health, Inc. (NYSE:ELV)

Representative Jared Moskowitz (D-Florida) recently sold shares of Elevance Health, Inc. NYSE: ELV. In a filing disclosed on April 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Elevance Health stock on March 10th. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (1)" account.

Representative Jared Moskowitz also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Broadcom NASDAQ: AVGO on 3/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 3/11/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of TJX Companies NYSE: TJX on 3/10/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 3/10/2025.
• Sold $1,001 - $15,000 in shares of West Pharmaceutical Services NYSE: WST on 2/13/2025.
• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 1/15/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 1/15/2025.
• Sold $1,001 - $15,000 in shares of Canadian National Railway NYSE: CNI on 1/15/2025.
• Purchased $1,001 - $15,000 in shares of Stryker NYSE: SYK on 1/15/2025.

Elevance Health Stock Down 0.8 %

ELV stock traded down $3.34 on Tuesday, reaching $437.83. 1,076,264 shares of the company traded hands, compared to its average volume of 1,441,292. The firm has a fifty day simple moving average of $414.67 and a 200-day simple moving average of $412.17. The company has a market cap of $99.12 billion, a P/E ratio of 17.10, a price-to-earnings-growth ratio of 1.18 and a beta of 0.77. Elevance Health, Inc. has a one year low of $362.21 and a one year high of $567.26. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50.

Remove Ads

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. Research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th were given a $1.71 dividend. This is a boost from Elevance Health's previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.56%. The ex-dividend date of this dividend was Monday, March 10th. Elevance Health's payout ratio is currently 26.71%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ELV. Cantor Fitzgerald reiterated an "overweight" rating and set a $485.00 price target on shares of Elevance Health in a report on Friday, January 24th. Barclays lifted their target price on Elevance Health from $501.00 to $512.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Argus raised Elevance Health from a "hold" rating to a "buy" rating and set a $450.00 price target on the stock in a report on Monday, March 17th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Elevance Health in a research report on Friday, March 28th. Finally, StockNews.com raised Elevance Health from a "hold" rating to a "buy" rating in a research report on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of "Moderate Buy" and an average price target of $514.41.

Insider Buying and Selling at Elevance Health

In other news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the completion of the transaction, the executive vice president now directly owns 10,116 shares in the company, valued at approximately $4,008,970.80. This represents a 25.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total transaction of $183,902.59. Following the sale, the chief accounting officer now directly owns 1,847 shares in the company, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Elevance Health

Large investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp lifted its stake in shares of Elevance Health by 2.5% during the 1st quarter. Fifth Third Bancorp now owns 16,607 shares of the company's stock valued at $7,223,000 after buying an additional 409 shares in the last quarter. Simon Quick Advisors LLC purchased a new stake in shares of Elevance Health during the first quarter worth about $336,000. Axecap Investments LLC bought a new stake in Elevance Health during the 1st quarter valued at approximately $1,131,000. Leonard Rickey Investment Advisors P.L.L.C. grew its holdings in Elevance Health by 11.7% during the 1st quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,185 shares of the company's stock valued at $523,000 after buying an additional 124 shares in the last quarter. Finally, CX Institutional lifted its holdings in shares of Elevance Health by 72.0% in the first quarter. CX Institutional now owns 1,486 shares of the company's stock worth $646,000 after buying an additional 622 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company's stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.